(:ADMS)

Business Focus: N/A

Nov 24, 2021 09:12 am ET

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy,...

Nov 23, 2021 08:00 am ET

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc....

Nov 09, 2021 12:12 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBI

NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Nov 08, 2021 07:23 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 8, 2021 /PRNewswire/ --

Nov 04, 2021 06:56 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the Firm

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Nov 02, 2021 08:20 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 2, 2021 /PRNewswire/ --

Nov 02, 2021 06:30 pm ET

ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. -

NEW ORLEANS, Nov. 2, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain conditions are met) for each share of Adamas that they own. KSF is seeking to dete

Oct 30, 2021 05:45 pm ET

STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, Oct. 30, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Oct 28, 2021 02:58 pm ET

Moore Kuehn Encourages PSXP, BRPM, HFC, and ADMS Investors to Contact Law Firm

Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...

Oct 28, 2021 02:25 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Oct 27, 2021 12:36 pm ET

ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors of its investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or...

Oct 26, 2021 09:48 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

NEW YORK, Oct. 26, 2021 /PRNewswire/ --

Oct 21, 2021 12:01 am ET

Lifshitz Law Firm, P.C. Announces Investigation of ADMS, ACBI, FLXN, and HBMD

Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS...

Oct 20, 2021 02:15 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KRA, EBMT, ESBK, ADMS; Shareholders are Encouraged to Contact the Firm

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Oct 19, 2021 01:50 pm ET

MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:

Oct 18, 2021 05:46 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

NEW YORK, Oct. 18, 2021 /PRNewswire/ --

Oct 18, 2021 11:52 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, AZPN, GSKY, GWB; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

Oct 15, 2021 10:46 pm ET

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Adamas Pharmaceuticals, Inc. ("ADMS" or the "Company") (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own.

Oct 15, 2021 02:14 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Oct 14, 2021 03:32 pm ET

ADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the...

Oct 14, 2021 02:35 pm ET

MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 14, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:

Oct 12, 2021 02:07 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the Firm

Oct 12, 2021 01:30 pm ET

MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:

Oct 12, 2021 12:25 pm ET

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Adamas Pharmaceuticals, Inc. Merger

Rigrodsky Law, P.A. announces that it is investigating Adamas Pharmaceuticals, Inc. (“Adamas”) (NASDAQ GM: ADMS) regarding possible breaches of fiduciary duties and other violations of law related to Adamas’ agreement to be acquired by Supernus...

Oct 12, 2021 12:20 pm ET

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. -

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain conditions are met) for each share of Adamas that they own. KSF is seeking to determine whether this consideration and the process

Oct 11, 2021 01:37 pm ET

Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus.

Oct 11, 2021 11:39 am ET

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders.

Oct 11, 2021 09:31 am ET

Thinking about buying stock in Adamas Pharmaceuticals, Trevi Therapeutics, Live Oak Acquisition, Comstock Resources, or Hallador Energy?

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMS, TRVI, LOKB, CRK, and HNRG.

Oct 11, 2021 06:30 am ET

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of...

Oct 08, 2021 04:15 pm ET

Adamas Announces New Employment Inducement Grants

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Oct 01, 2021 09:15 am ET

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year’s UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories. Companies selected as finalists have been evaluated on innovation, impact, and value of their product to improve patient outcomes

Sep 16, 2021 09:15 am ET

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based the

Sep 10, 2021 05:00 pm ET

Adamas Announces New Employment Inducement Grants

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Aug 30, 2021 04:11 pm ET

Adamas to Present at Upcoming September Investor Conferences

Aug 13, 2021 04:16 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 38,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Aug 09, 2021 04:01 pm ET

Adamas Reports Second Quarter 2021 Financial Results

Aug 02, 2021 04:02 pm ET

Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Jul 22, 2021 09:15 am ET

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI® (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021. These two patents are the first issued in this patent family and provide additional claims covering the drug product GOCOVRI, the company’s medicine approved as the first and only drug to treat

Jul 09, 2021 04:05 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees restricted stock units to acquire 44,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Jul 08, 2021 04:02 pm ET

Adamas to Present at Upcoming William Blair Biotech Focus Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 1:00 pm Eastern Time.

Jun 23, 2021 04:42 pm ET

Adamas to Present at Upcoming SVB Leerink CNS Forum

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the company will present “What’s Happening in Parkinson’s Disease & the GOCOVRI Opportunity” at the SVB Leerink CNS Forum on Tuesday, June 29th at 1:10 pm Eastern Time.

Jun 11, 2021 04:08 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Jun 10, 2021 09:15 am ET

New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, “Effects of GOCOVRI® (amantadine) extended-release capsules on motor as

May 27, 2021 04:11 pm ET

Adamas to Present at Upcoming June Conferences

May 10, 2021 04:02 pm ET

Adamas Reports First Quarter 2021 Financial Results

May 07, 2021 04:05 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees restricted stock units to acquire 58,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Apr 29, 2021 04:04 pm ET

Adamas to Present at Upcoming BofA Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021.

Apr 27, 2021 09:15 am ET

Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the launch of “Picture More Time,” a disease education campaign focused on raising awareness and understanding of OFF time and dyskinesia and the

Apr 26, 2021 04:04 pm ET

Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Apr 19, 2021 09:15 am ET

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting

Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced findings from a survey on the impact of OFF time and dyskinesia, also k

Apr 15, 2021 09:15 am ET

Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an a

Apr 07, 2021 05:19 pm ET

Adamas to Present at Upcoming Needham Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12 – 15, 2021.

Mar 29, 2021 09:15 am ET

Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease

Mar 05, 2021 04:02 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Mar 01, 2021 04:04 pm ET

Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of its previously announced underwritten public offering of 12,500,000 shares of its common stock, plus the exercise in full by the underwriters of their option to purchase an additional 1,875,000 shares, at a price to the public of $4.40 per share. The estimated net proceeds of the offering to Adamas, after deducting underwriting discounts and commissions and other offering expenses, a

Feb 24, 2021 09:16 pm ET

Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $55.0 million, excluding any exercise of the underwriters

Feb 24, 2021 04:08 pm ET

Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can

Feb 23, 2021 04:03 pm ET

Adamas Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 17, 2021 04:06 pm ET

Adamas to Present at Upcoming Healthcare Conferences

Feb 10, 2021 09:24 am ET

Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Feb 01, 2021 02:07 pm ET

Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes, in addition to its indication for the

Feb 01, 2021 08:01 am ET

Adamas Announces Settlement of Patent Litigation with Zydus

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a settlement agreement with Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc. (“Zydus”) resolving its ongoing litigation concerning Zydus’s Abbreviated New Drug Application (“ANDA”) seeking approval by the U.S. Food and Drug Administration to market a generic version of GOCOVRI® (amantadine) extended-release capsules.

Jan 13, 2021 09:15 am ET

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

Jan 07, 2021 06:02 pm ET

Adamas to Present at Upcoming ICR Conference

Jan 05, 2021 09:15 am ET

Adamas Completes Acquisition of OSMOLEX ER®

Jan 04, 2021 04:15 pm ET

Adamas to Present at Upcoming H.C. Wainwright Conference

Dec 11, 2020 04:02 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per...

Dec 02, 2020 06:51 am ET

Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners

Dec 02, 2020 06:50 am ET

Adamas Announces Agreement to Settle Patent Litigation with Osmotica

Nov 24, 2020 04:03 pm ET

Adamas to Present at Upcoming Evercore ISI Conference

Nov 23, 2020 09:15 am ET

Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD,...

Nov 18, 2020 04:02 pm ET

Adamas to Present at Upcoming Piper Sandler Conference

Nov 13, 2020 04:05 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 45,000 shares of the company’s common stock, at a per...

Nov 05, 2020 04:03 pm ET

Adamas Reports Third Quarter 2020 Financial Results

Nov 02, 2020 09:25 am ET

Adamas announces settlement agreement of previously disclosed class action litigation

Oct 26, 2020 04:04 pm ET

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...

Oct 09, 2020 04:03 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 161,000 shares of the company’s common stock, at a per...

Oct 01, 2020 09:15 am ET

Adamas appoints new Chief Medical Officer, Adrian Quartel, MD

Sep 11, 2020 04:04 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per...

Sep 11, 2020 09:15 am ET

Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine)...

Sep 08, 2020 04:05 pm ET

Adamas to Present at Upcoming HC Wainwright Conference

Sep 01, 2020 09:15 am ET

Adamas Appoints Anna Richo to Board of Directors

Aug 14, 2020 04:04 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 36,000 shares of the company’s common stock, at a per...

Aug 06, 2020 04:02 pm ET

Adamas Reports Second Quarter 2020 Financial Results

Jul 23, 2020 04:02 pm ET

Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...

Jul 15, 2020 08:00 am ET

Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform

Jul 10, 2020 04:05 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 62,500 shares of the company’s common stock, at a per...

Jun 17, 2020 04:01 pm ET

Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment

Jun 04, 2020 04:30 pm ET

Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

Jun 03, 2020 04:01 pm ET

Adamas to Present at Upcoming William Blair Conference

May 13, 2020 09:15 am ET

Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time

May 08, 2020 06:46 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 66,000 shares of the company’s common stock, at a per...

May 07, 2020 04:03 pm ET

Adamas Reports First Quarter 2020 Financial Results

Apr 27, 2020 04:03 pm ET

Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...

Apr 10, 2020 04:06 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees the option to purchase an aggregate of 86,000 shares of the company’s common stock, at a per...

Mar 23, 2020 03:15 pm ET

Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors – ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals, Inc. On March 16, 2020, a verified...

Mar 19, 2020 04:46 pm ET

Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

PHILADELPHIA, March 19, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals, Inc.

Mar 06, 2020 04:39 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a per...

Feb 25, 2020 04:03 pm ET

Adamas Reports Fourth Quarter and Full Year 2019 Financial Results

Feb 20, 2020 04:01 pm ET

Adamas to Present at Upcoming Healthcare Conferences

Feb 19, 2020 04:02 pm ET

Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...

Feb 13, 2020 09:00 am ET

Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

Feb 11, 2020 04:15 pm ET

Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a clinically meaningful difference for people affected by neurological diseases, today announced the publication of final results from...

Feb 10, 2020 10:00 am ET

ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

Feb 07, 2020 10:00 am ET

DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adamas Pharmaceuticals, Inc. (“Adamas” or the Company”) (NASDAQ: ADMS) and certain of its officers, on behalf of...

Feb 05, 2020 11:26 am ET

ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS). If you purchased Adamas stock pursuant to the Company’s January 24, 2018...

Feb 04, 2020 01:41 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....

Feb 04, 2020 12:00 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...

Feb 04, 2020 11:12 am ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...

Feb 03, 2020 01:00 pm ET

DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Feb 03, 2020 10:11 am ET

ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Feb 01, 2020 02:00 pm ET

ADMS FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

Jan 31, 2020 02:22 pm ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Jan 31, 2020 01:37 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 31, 2020 11:16 am ET

ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:ADMS) of the February 10, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jan 29, 2020 01:19 pm ET

ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm

Jan 29, 2020 11:30 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Jan 29, 2020 09:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against X Financial, Baozun, Adamas Pharmaceuticals, and Cintas and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of X Financial (NYSE: XYF), Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals,...

Jan 28, 2020 10:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 27, 2020 05:06 pm ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Jan 27, 2020 11:00 am ET

DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 24, 2020 10:00 am ET

INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Jan 23, 2020 05:44 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 23, 2020 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Jan 22, 2020 02:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Fir

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS),...

Jan 22, 2020 01:19 pm ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Jan 21, 2020 05:50 pm ET

ADMS INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

Jan 21, 2020 11:00 am ET

DEADLINE ALERT for HEXO, XYF, BZUN, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 17, 2020 12:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 16, 2020 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Jan 15, 2020 04:32 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Fir

Jan 14, 2020 04:02 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

Jan 13, 2020 01:13 pm ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Jan 13, 2020 11:00 am ET

DEADLINE ALERT for HEXO, XYF, ADMS, EXC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 10, 2020 04:30 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 12,000 shares of the company’s common stock, at a per...

Jan 10, 2020 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Jan 10, 2020 10:00 am ET

INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines

Jan 09, 2020 03:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Adamas Pharmaceuticals, Cintas, Correvio Pharma, and Exelon and Encourages Investors to Contact the Fir

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Cintas Corporation (NASDAQ:...

Jan 09, 2020 08:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

NEW YORK, Jan. 9, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Jan 08, 2020 12:24 pm ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Jan 08, 2020 09:15 am ET

Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020

Jan 06, 2020 01:00 pm ET

DEADLINE ALERT for YJ, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Jan 06, 2020 09:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 04, 2020 11:00 am ET

ADMS INVESTOR ALERT: ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

Jan 03, 2020 06:54 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Jan 03, 2020 11:30 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Jan 02, 2020 12:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Net 1 UEPS Technologies, X Financial, Baozun, and Adamas Pharmaceuticals and Encourages Investors to Co

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS), X Financial (NYSE: XYF), Baozun,...

Jan 02, 2020 09:00 am ET

Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

Dec 31, 2019 02:53 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Dec 30, 2019 12:30 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Dec 27, 2019 11:47 am ET

ROSEN, NATIONAL TRIAL LAWYERS, Reminds Adamas Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – ADMS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Adamas investors under the federal securities laws.

Dec 23, 2019 05:44 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Dec 23, 2019 12:00 pm ET

DEADLINE ALERT for UNIT, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Dec 20, 2019 12:00 pm ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Dec 20, 2019 10:00 am ET

SHAREHOLDER ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adamas Pharmaceuticals, Inc. (“Adamas” or the Company”) (Nasdaq: ADMS) and certain of its officers, on behalf of...

Dec 19, 2019 07:12 pm ET

EQUITY ALERT: ROSEN LAW FIRM Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. – ADMS

Dec 18, 2019 12:00 pm ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) securities between August 8, 2017 and September 30, 2019, inclusiv

Dec 17, 2019 06:18 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:

Dec 17, 2019 04:41 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Dec 17, 2019 09:00 am ET

Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment

Dose-response observed for both efficacy and safety - - Safety data consistent with known safety profile of amantadine - EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to...

Dec 13, 2019 04:00 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:

Dec 13, 2019 01:36 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceuticals, Inc. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) securities between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”). Adamas investors have until February 10, 2020

Dec 12, 2019 08:43 pm ET

Shareholder Alert: Robbins LLP Announces Adamas Pharmaceuticals, Inc. (ADMS) Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a purchaser of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between August 8, 2017 and September 30, 2019. Adamas is a commercial stage pharmaceutical company that specializes in dev

Dec 12, 2019 08:00 pm ET

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) investors concerning the Company and its officers’ possible violations of federal securities laws.

Dec 12, 2019 06:19 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) investors concerning the Company and its officers’ possible violations of federal securities laws.

Dec 12, 2019 01:02 pm ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:

Dec 11, 2019 05:46 pm ET

ADMS LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. – ADMS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Adamas investors under the federal securities laws.

Dec 11, 2019 04:16 pm ET

IMPORTANT INVESTOR ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:

Dec 09, 2019 04:50 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per...

Nov 21, 2019 04:02 pm ET

Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is...

Nov 08, 2019 04:01 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 14,500 shares of the company’s common stock, at a per...

Nov 07, 2019 04:03 pm ET

Adamas Reports Third Quarter 2019 Financial Results

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2019,...

Oct 30, 2019 04:30 pm ET

Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and...

Oct 08, 2019 04:03 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 44,375 shares of the company’s common stock, at a per...

Sep 27, 2019 04:05 pm ET

Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference

Sep 20, 2019 08:00 am ET

Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI® (amantadine) extended...

Sep 17, 2019 04:15 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted its new Chief Executive Officer, Neil F. McFarlane, the option to purchase an aggregate of 250,000 shares of the...

Sep 13, 2019 07:30 am ET

Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil McFarlane has been named Chief Executive Officer and...

Sep 10, 2019 04:15 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 17,250 shares of the company’s common stock, at a per...

Aug 12, 2019 05:07 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 5,000 shares of the company’s common stock, at a per...

Aug 08, 2019 04:02 pm ET

Adamas Reports Second Quarter 2019 Financial Results

Jul 23, 2019 04:05 pm ET

Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday, August 8, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and...

Jul 16, 2019 05:03 pm ET

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM: ADMS) concerning possible violations of federal securities laws. According to a recently filed...

Jul 08, 2019 04:29 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 11,000 shares of the company’s common stock, at a per...

Jun 18, 2019 04:05 pm ET

Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Diseas

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 trials of...

Jun 17, 2019 05:54 pm ET

ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (Nasdaq: ADMS), including investors who purchased Adamas common stock directly in the Company’s January 24

Jun 17, 2019 05:23 pm ET

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

Jun 12, 2019 07:05 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....

Jun 10, 2019 09:00 am ET

ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Ad

Jun 07, 2019 05:30 pm ET

Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 148,500 shares of the company’s common stock, at a...

Jun 04, 2019 11:49 am ET

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Jun 03, 2019 04:31 pm ET

Adamas to Present at Upcoming JMP Investor Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief...

May 31, 2019 11:45 am ET

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir

May 30, 2019 07:03 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

May 30, 2019 06:31 pm ET

ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

May 30, 2019 04:30 pm ET

Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as its Chief...

May 29, 2019 10:32 am ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 28, 2019 09:00 pm ET

Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on behalf of Adamas stockholders. Our investigation concerns whether Adamas has violated the federal securities laws and/or engaged...

May 28, 2019 05:55 pm ET

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

May 28, 2019 03:58 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

You are here

(:ADMS)

Business Focus: N/A